ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
Supports innovative research to develop and validate biomarkers that improve diagnosis and treatment of frontotemporal degeneration (FTD).
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): February 2027 (Letter of Intent) | April 2027 (Full Application)
Funding Amounts: Typical awards range from $250,000 to $1.2 million per project; award size varies by project scope and duration.
Summary: Supports innovative research to develop biomarkers for frontotemporal degeneration, accelerating FTD diagnosis and treatment.
Description
This funding opportunity, offered through a partnership between the Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD), is designed to catalyze the development of biomarkers for frontotemporal degeneration (FTD). The Diagnostics Accelerator leverages venture philanthropy to support high-risk, high-reward research projects that may not yield immediate commercial gains but are critical for advancing practical diagnostic tools and therapies for FTD. The program welcomes proposals that address unmet needs in FTD biomarker discovery, validation, and translation, aiming to improve disease detection and guide future therapeutic development.
